{"title_page": "Pretomanid", "text_new": "{{short description|Chemical compound}}\n{{Use dmy dates|date=March 2020}}\n{{Infobox drug\n| drug_name         =\n| INN               =\n| type              =<!-- empty -->\n| IUPAC_name        = (6''S'')-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5''H''-imidazo[2,1-''b''][1,3]oxazine\n| image             = Pretomanid.svg\n| alt               = \n| caption           =\n<!-- Clinical data -->\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->\n| pregnancy_AU_comment = \n| pregnancy_US      = <!-- A/B/C/D/X/N -->\n| pregnancy_category= \n| routes_of_administration = Oral\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_AU_comment =\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_DE = <!-- Anlage I, II, III -->\n| legal_NZ = <!-- Class A, B, C -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->\n| legal_US = Rx-only\n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_status      = \n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action =\n| excretion         = \n<!-- Identifiers -->\n| CAS_number        = 187235-37-6\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 2XOI31YC4N\n| class             = \n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n| PubChem = 456199\n| DrugBank          = \n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 227875\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 401693\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10722\n<!-- Chemical and physical data -->\n| C=14|H=12|F=3|N=3|O=5\n| smiles= [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc3ccc(OC(F)(F)F)cc3\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = ZLHZLMOSPGACSZ-NSHDSACASA-N\n}}\n<!-- Definition and medical uses -->\n'''Pretomanid''' is an [[antibiotic]] used for the treatment of [[multi-drug-resistant tuberculosis]] affecting the [[lungs]].<ref name=FDA2019>{{cite press release |title=FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs |website=U.S. [[Food and Drug Administration]] (FDA) |accessdate=28 August 2019 |date=14 August 2019}} {{PD-notice}}</ref><ref>{{cite web | title=Drug Trials Snapshots: Pretomanid | website=U.S. [[Food and Drug Administration]] (FDA) | date=14 August 2019 | url=http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pretomanid | access-date=17 March 2020}}</ref> It is generally used together with [[bedaquiline]] and [[linezolid]].<ref name=FDA2019/> It is taken by mouth.<ref name=FDA2019/>\n\n<!-- Side effects and mechanism -->\nThe most common side effects include [[peripheral neuropathy|nerve damage]], [[acne]], vomiting, headache, [[Hypoglycemia|low blood sugar]], diarrhea, and [[Hepatitis|liver inflammation]].<ref name=FDA2019/> It is in the [[nitroimidazole]] class of medications.<ref>{{cite web|url=https://www.tballiance.org/portfolio/compound/pretomanid|title=Compounds|website=TB Alliance|access-date=18 April 2019}}</ref> \n\n<!-- History and culture -->\nPretomanid was approved for medical use in the United States in 2019.<ref name=FDA2019/> Pretomanid was developed by [[TB Alliance]].<ref>{{cite web|url=https://www.tballiance.org/news/pretomanid-enters-FDA-review|title=TB Medicine Pretomanid Enters Regulatory Review Process in the United States|website=[[TB Alliance]]|access-date=18 April 2019}}</ref><ref name=FDA2019/><ref name=approval>{{cite web | last = Abutaleb | first = Yasmeen | name-list-format = vanc | url = https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html | title = New antibiotic approved for drug-resistant tuberculosis | work = [[The Washington Post]] | date = 14 August 2019 }}</ref>\n\n== History ==\nPretomanid is the generic, nonproprietary name for the novel anti-bacterial drug compound formerly called PA-824.<ref>{{cite web|url=https://www.tballiance.org/news/pa-824-has-new-generic-name-pretomanid|title=PA-824 has a New Generic Name: Pretomanid |website=TB Alliance |access-date=18 April 2019}}</ref>  Pretomanid is referred to as \"Pa\" in regimen abbreviations, such as BPaL. The \"preto\" prefix of the compound's name honors Pretoria, South Africa, the home of a TB Alliance clinical development office where much of the drug's development took place. The \"manid\" suffix is used to group compounds with similar chemical structures.  This class of drug is variously referred to as [[nitroimidazole]]s, nitroimidazooxazines or nitroimidazopyrans.  Development of this compound was initiated because of the urgent need for new antibacterial drugs effective against resistant strains of tuberculosis. Also, current anti-TB drugs are mainly effective against replicating and metabolically active bacteria, creating a need for drugs effective against persisting or latent bacterial infections as often occur in patients with tuberculosis.<ref name=\"Lenaerts_2005\">{{cite journal | vauthors = Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM | title = Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models | journal = Antimicrobial Agents and Chemotherapy | volume = 49 | issue = 6 | pages = 2294\u2013301 | date = June 2005 | pmid = 15917524 | pmc = 1140539 | doi = 10.1128/AAC.49.6.2294-2301.2005 }}</ref>\n\n===Discovery and pre-clinical development===\nPretomanid was first identified in 2000 in a series of 100 nitroimidazopyran derivatives synthesized and tested for antitubercular activity, by PathoGenesis (now a subsidiary of Novartis).<ref name=\"Stover2000\">{{cite journal | vauthors = Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR | journal = Nature | year = 2000 | volume = 405 | issue = 6789 | pages = 962\u20136 |\ntitle = A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. | doi = 10.1038/35016103 | pmid = 10879539 | bibcode = 2000Natur.405..962S }}</ref> Importantly, pretomanid has activity against static ''M. tuberculosis'' isolates that survive under anaerobic conditions, with bactericidal activity comparable to that of the existing drug [[metronidazole]].  Pretomanid requires metabolic activation by ''Mycobacterium'' for antibacterial activity.  Pretomanid was not the most potent compound in the series against cultures of ''M. tuberculosis'', but it was the most active in infected mice after oral administration. Oral pretomanid was active against tuberculosis in mice and guinea pigs at safely tolerated dosages for up to 28 days.<ref name=\"Lenaerts_2005\" />\n\n===Limited FDA approval===\nFDA approved pretomanid only in combination with [[bedaquiline]] and [[linezolid]] for treatment of a limited and specific population of adult patients with [[Extensively drug-resistant tuberculosis|extensively drug resistant]], treatment-intolerant or nonresponsive [[multidrug resistant tuberculosis|multidrug resistant]] pulmonary tuberculosis.<ref name=FDA2019 /> Pretomanid was approved under the Limited Population Pathway (LPAD pathway) for antibacterial and antifungal drugs.<ref name=FDA2019 /> The LPAD Pathway was established by Congress under the [[21st Century Cures Act]] to expedite development and approval of [[Antibacterial agent|antibacterial]] and [[antifungal drug|antifungal]] drugs to treat serious or life-threatening infections in a limited population of patients with unmet need. Pretomanid is only the third tuberculosis drug to receive FDA approval in more than 40 years.<ref name=FDA2019 /><ref name=approval/>\n\nThe FDA granted Pretomanid [[priority review]] and [[orphan drug]] designation.<ref name=FDA2019 /> The FDA granted The Global Alliance for TB Drug Development ([[TB Alliance]]) the approval of Pretomanid and a Tropical Disease Priority Review Voucher.<ref name=FDA2019 />\n\n== See also ==\n* [[Delamanid]], a related drug\n\n== References ==\n{{reflist}}\n\n==External links==\n* {{cite web| url = https://druginfo.nlm.nih.gov/drugportal/name/pretomanid | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Pretomanid }}\n\n{{Portal bar | Pharmacy and pharmacology | Medicine}}\n\n[[Category:Anti-tuberculosis drugs]]\n[[Category:Orphan drugs]]\n[[Category:Prodrugs]]\n[[Category:Trifluoromethoxy compounds]]\n", "text_old": "{{short description|Chemical compound}}\n{{Use dmy dates|date=March 2020}}\n{{Infobox drug\n| drug_name         =\n| INN               =\n| type              =<!-- empty -->\n| IUPAC_name        = (6''S'')-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5''H''-imidazo[2,1-''b''][1,3]oxazine\n| image             = Pretomanid.svg\n| alt               = \n| caption           =\n<!-- Clinical data -->\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->\n| pregnancy_AU_comment = \n| pregnancy_US      = <!-- A/B/C/D/X/N -->\n| pregnancy_category= \n| routes_of_administration = Oral\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_AU_comment =\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_DE = <!-- Anlage I, II, III -->\n| legal_NZ = <!-- Class A, B, C -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->\n| legal_US = Rx-only\n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_status      = \n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action =\n| excretion         = \n<!-- Identifiers -->\n| CAS_number        = 187235-37-6\n| class             = \n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n| PubChem = 456199\n| DrugBank          = \n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 227875\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 401693\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10722\n<!-- Chemical and physical data -->\n| C=14|H=12|F=3|N=3|O=5\n| smiles= [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc3ccc(OC(F)(F)F)cc3\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = ZLHZLMOSPGACSZ-NSHDSACASA-N\n}}\n<!-- Definition and medical uses -->\n'''Pretomanid''' is an [[antibiotic]] used for the treatment of [[multi-drug-resistant tuberculosis]] affecting the [[lungs]].<ref name=FDA2019>{{cite press release |title=FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs |website=U.S. [[Food and Drug Administration]] (FDA) |accessdate=28 August 2019 |date=14 August 2019}} {{PD-notice}}</ref><ref>{{cite web | title=Drug Trials Snapshots: Pretomanid | website=U.S. [[Food and Drug Administration]] (FDA) | date=14 August 2019 | url=http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pretomanid | access-date=17 March 2020}}</ref> It is generally used together with [[bedaquiline]] and [[linezolid]].<ref name=FDA2019/> It is taken by mouth.<ref name=FDA2019/>\n\n<!-- Side effects and mechanism -->\nThe most common side effects include [[peripheral neuropathy|nerve damage]], [[acne]], vomiting, headache, [[Hypoglycemia|low blood sugar]], diarrhea, and [[Hepatitis|liver inflammation]].<ref name=FDA2019/> It is in the [[nitroimidazole]] class of medications.<ref>{{cite web|url=https://www.tballiance.org/portfolio/compound/pretomanid|title=Compounds|website=TB Alliance|access-date=18 April 2019}}</ref> \n\n<!-- History and culture -->\nPretomanid was approved for medical use in the United States in 2019.<ref name=FDA2019/> Pretomanid was developed by [[TB Alliance]].<ref>{{cite web|url=https://www.tballiance.org/news/pretomanid-enters-FDA-review|title=TB Medicine Pretomanid Enters Regulatory Review Process in the United States|website=[[TB Alliance]]|access-date=18 April 2019}}</ref><ref name=FDA2019/><ref name=approval>{{cite web | last = Abutaleb | first = Yasmeen | name-list-format = vanc | url = https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html | title = New antibiotic approved for drug-resistant tuberculosis | work = [[The Washington Post]] | date = 14 August 2019 }}</ref>\n\n== History ==\nPretomanid is the generic, nonproprietary name for the novel anti-bacterial drug compound formerly called PA-824.<ref>{{cite web|url=https://www.tballiance.org/news/pa-824-has-new-generic-name-pretomanid|title=PA-824 has a New Generic Name: Pretomanid |website=TB Alliance |access-date=18 April 2019}}</ref>  Pretomanid is referred to as \"Pa\" in regimen abbreviations, such as BPaL. The \"preto\" prefix of the compound's name honors Pretoria, South Africa, the home of a TB Alliance clinical development office where much of the drug's development took place. The \"manid\" suffix is used to group compounds with similar chemical structures.  This class of drug is variously referred to as [[nitroimidazole]]s, nitroimidazooxazines or nitroimidazopyrans.  Development of this compound was initiated because of the urgent need for new antibacterial drugs effective against resistant strains of tuberculosis. Also, current anti-TB drugs are mainly effective against replicating and metabolically active bacteria, creating a need for drugs effective against persisting or latent bacterial infections as often occur in patients with tuberculosis.<ref name=\"Lenaerts_2005\">{{cite journal | vauthors = Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM | title = Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models | journal = Antimicrobial Agents and Chemotherapy | volume = 49 | issue = 6 | pages = 2294\u2013301 | date = June 2005 | pmid = 15917524 | pmc = 1140539 | doi = 10.1128/AAC.49.6.2294-2301.2005 }}</ref>\n\n===Discovery and pre-clinical development===\nPretomanid was first identified in 2000 in a series of 100 nitroimidazopyran derivatives synthesized and tested for antitubercular activity, by PathoGenesis (now a subsidiary of Novartis).<ref name=\"Stover2000\">{{cite journal | vauthors = Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR | journal = Nature | year = 2000 | volume = 405 | issue = 6789 | pages = 962\u20136 |\ntitle = A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. | doi = 10.1038/35016103 | pmid = 10879539 | bibcode = 2000Natur.405..962S }}</ref> Importantly, pretomanid has activity against static ''M. tuberculosis'' isolates that survive under anaerobic conditions, with bactericidal activity comparable to that of the existing drug [[metronidazole]].  Pretomanid requires metabolic activation by ''Mycobacterium'' for antibacterial activity.  Pretomanid was not the most potent compound in the series against cultures of ''M. tuberculosis'', but it was the most active in infected mice after oral administration. Oral pretomanid was active against tuberculosis in mice and guinea pigs at safely tolerated dosages for up to 28 days.<ref name=\"Lenaerts_2005\" />\n\n===Limited FDA approval===\nFDA approved pretomanid only in combination with [[bedaquiline]] and [[linezolid]] for treatment of a limited and specific population of adult patients with [[Extensively drug-resistant tuberculosis|extensively drug resistant]], treatment-intolerant or nonresponsive [[multidrug resistant tuberculosis|multidrug resistant]] pulmonary tuberculosis.<ref name=FDA2019 /> Pretomanid was approved under the Limited Population Pathway (LPAD pathway) for antibacterial and antifungal drugs.<ref name=FDA2019 /> The LPAD Pathway was established by Congress under the [[21st Century Cures Act]] to expedite development and approval of [[Antibacterial agent|antibacterial]] and [[antifungal drug|antifungal]] drugs to treat serious or life-threatening infections in a limited population of patients with unmet need. Pretomanid is only the third tuberculosis drug to receive FDA approval in more than 40 years.<ref name=FDA2019 /><ref name=approval/>\n\nThe FDA granted Pretomanid [[priority review]] and [[orphan drug]] designation.<ref name=FDA2019 /> The FDA granted The Global Alliance for TB Drug Development ([[TB Alliance]]) the approval of Pretomanid and a Tropical Disease Priority Review Voucher.<ref name=FDA2019 />\n\n== See also ==\n* [[Delamanid]], a related drug\n\n== References ==\n{{reflist}}\n\n==External links==\n* {{cite web| url = https://druginfo.nlm.nih.gov/drugportal/name/pretomanid | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Pretomanid }}\n\n{{Portal bar | Pharmacy and pharmacology | Medicine}}\n\n[[Category:Anti-tuberculosis drugs]]\n[[Category:Orphan drugs]]\n[[Category:Prodrugs]]\n[[Category:Trifluoromethoxy compounds]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Pretomanid"}
